AP2408A - Pyridine[3,4-B]pyrazinones. - Google Patents

Pyridine[3,4-B]pyrazinones.

Info

Publication number
AP2408A
AP2408A AP2008004640A AP2008004640A AP2408A AP 2408 A AP2408 A AP 2408A AP 2008004640 A AP2008004640 A AP 2008004640A AP 2008004640 A AP2008004640 A AP 2008004640A AP 2408 A AP2408 A AP 2408A
Authority
AP
ARIPO
Prior art keywords
pyrazinones
pyridine
Prior art date
Application number
AP2008004640A
Other languages
English (en)
Other versions
AP2008004640A0 (en
Inventor
Andrew Simon Bell
David Louis Brown
David Graham Brown
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004640A0 publication Critical patent/AP2008004640A0/xx
Application granted granted Critical
Publication of AP2408A publication Critical patent/AP2408A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
AP2008004640A 2006-04-21 2007-04-10 Pyridine[3,4-B]pyrazinones. AP2408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (fr) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (2)

Publication Number Publication Date
AP2008004640A0 AP2008004640A0 (en) 2008-10-31
AP2408A true AP2408A (en) 2012-05-30

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004640A AP2408A (en) 2006-04-21 2007-04-10 Pyridine[3,4-B]pyrazinones.

Country Status (41)

Country Link
US (1) US7902195B2 (fr)
EP (1) EP2013208B1 (fr)
JP (1) JP4436892B2 (fr)
KR (1) KR101061328B1 (fr)
CN (1) CN101454320B (fr)
AP (1) AP2408A (fr)
AR (1) AR060525A1 (fr)
AT (1) ATE513831T1 (fr)
AU (1) AU2007242555B2 (fr)
BR (1) BRPI0710658A2 (fr)
CA (1) CA2649775C (fr)
CR (1) CR10327A (fr)
CU (1) CU23777B7 (fr)
CY (1) CY1111739T1 (fr)
DK (1) DK2013208T3 (fr)
DO (1) DOP2007000080A (fr)
EA (1) EA014919B1 (fr)
EC (1) ECSP088803A (fr)
ES (1) ES2366239T3 (fr)
GT (1) GT200700035A (fr)
HR (1) HRP20110539T1 (fr)
IL (1) IL194591A (fr)
MA (1) MA30352B1 (fr)
ME (1) MEP23808A (fr)
MX (1) MX2008012456A (fr)
MY (1) MY148583A (fr)
NL (1) NL2000583C2 (fr)
NO (1) NO20084129L (fr)
NZ (1) NZ571540A (fr)
PA (1) PA8724201A1 (fr)
PE (1) PE20080192A1 (fr)
PL (1) PL2013208T3 (fr)
RS (2) RS51885B (fr)
SI (1) SI2013208T1 (fr)
SV (1) SV2008003074A (fr)
TN (1) TNSN08408A1 (fr)
TW (1) TWI337609B (fr)
UA (1) UA92637C2 (fr)
UY (1) UY30291A1 (fr)
WO (1) WO2007122466A1 (fr)
ZA (1) ZA200808283B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007242555B2 (en) 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
PT2247292T (pt) 2008-03-05 2017-07-17 Merck Patent Gmbh Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes
WO2010041711A1 (fr) * 2008-10-09 2010-04-15 杏林製薬株式会社 Dérivé d'isoquinoléine et inhibiteur de la pde le comportant en tant qu’ingrédient actif
SG10201500511TA (en) * 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
CA2830027C (fr) 2011-03-31 2016-04-26 Pfizer Inc. Nouvelles pyridones bicycliques
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
AP2016009465A0 (en) 2014-04-01 2016-09-30 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4,4a,5,6‑四氢吡喃并[3,4‑d][1,3]噻嗪‑8a(8H)‑基‑1,3‑噻唑‑4‑基酰胺
WO2016012896A1 (fr) 2014-07-24 2016-01-28 Pfizer Inc. Composés de pyrazolopyrimidine
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド
WO2017051303A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド
CN113332292A (zh) 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
PT3478679T (pt) 2016-07-01 2021-06-30 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas
IL271290B2 (en) 2017-06-22 2023-11-01 Pfizer Dihydro-pyrrolo-pyridine derivatives
US11382918B2 (en) * 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
PT3768669T (pt) 2018-03-23 2023-04-24 Pfizer Derivados de piperazina azaspiro
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies
WO2025160132A1 (fr) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Agonistes inverses de gpr6

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (fr) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
WO2006126082A2 (fr) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
TW274550B (fr) 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
WO2002076954A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
EP1641423B1 (fr) 2003-06-26 2010-03-17 Merck Sharp & Dohme Corp. Benzodiazepines antagonistes du recepteur cgrp
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
EP1833803A4 (fr) 2005-01-03 2009-08-05 Myriad Genetics Inc Composes pharmaceutiques constituant des activateurs de caspases et des inducteurs d'apoptose et utilisation de ces composes
JP2009509923A (ja) 2005-08-26 2009-03-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
AU2007242555B2 (en) 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (fr) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
WO2006126082A2 (fr) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones

Also Published As

Publication number Publication date
MEP23808A (en) 2010-06-10
TWI337609B (en) 2011-02-21
KR20080110930A (ko) 2008-12-19
CR10327A (es) 2008-10-21
RS20080484A (sr) 2009-07-15
US20070249615A1 (en) 2007-10-25
UY30291A1 (es) 2007-11-30
KR101061328B1 (ko) 2011-08-31
EA200801998A1 (ru) 2009-04-28
EA014919B1 (ru) 2011-04-29
JP4436892B2 (ja) 2010-03-24
NL2000583A1 (nl) 2007-10-23
TNSN08408A1 (fr) 2010-04-14
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
NO20084129L (no) 2008-10-29
MA30352B1 (fr) 2009-04-01
HRP20110539T1 (hr) 2011-08-31
ZA200808283B (en) 2009-11-25
HK1133875A1 (en) 2010-04-09
CA2649775C (fr) 2011-05-31
SI2013208T1 (sl) 2011-09-30
PE20080192A1 (es) 2008-03-01
MY148583A (en) 2013-04-30
GT200700035A (es) 2008-02-05
EP2013208A1 (fr) 2009-01-14
ATE513831T1 (de) 2011-07-15
RS51885B (sr) 2012-02-29
CU20080194A7 (es) 2011-03-21
CA2649775A1 (fr) 2007-11-01
EP2013208B1 (fr) 2011-06-22
WO2007122466A1 (fr) 2007-11-01
AU2007242555B2 (en) 2010-12-16
CN101454320B (zh) 2012-12-19
CY1111739T1 (el) 2015-10-07
PA8724201A1 (es) 2009-08-26
NZ571540A (en) 2010-10-29
IL194591A (en) 2012-07-31
AU2007242555A1 (en) 2007-11-01
TW200808794A (en) 2008-02-16
US7902195B2 (en) 2011-03-08
PL2013208T3 (pl) 2011-10-31
ES2366239T3 (es) 2011-10-18
ECSP088803A (es) 2008-11-27
AP2008004640A0 (en) 2008-10-31
SV2008003074A (es) 2010-01-12
CU23777B7 (es) 2012-02-15
BRPI0710658A2 (pt) 2011-08-16
MX2008012456A (es) 2008-10-10
DK2013208T3 (da) 2011-08-15
CN101454320A (zh) 2009-06-10
JP2009534368A (ja) 2009-09-24
DOP2007000080A (es) 2007-11-15
AR060525A1 (es) 2008-06-25

Similar Documents

Publication Publication Date Title
AP2408A (en) Pyridine[3,4-B]pyrazinones.
IL201973A0 (en) 3,3-spiroindolinone derivatives
SI2334687T1 (sl) Dioksa biciklo oktan triol derivati
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
IL198250A0 (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b
IL195915A0 (en) 3-amino -imidazo[1,2-a]pyridine derivatives as sglt inhibitors
PL2155712T3 (pl) 3-(imidazolilo)-pirazolo[3,4-b]pirydyny
DE602007005775D1 (en) 6-phenyl-1h-imidazoä4, 5-cüpyridin-4-carbonitril-derivate als cathepsin-k- und -s-hemmer
ZA200805756B (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivative
PL1889848T3 (pl) 6,7-nienasycona-7-karbamoilo-podstawiona pochodna morfinanu
IL241548A0 (en) Antibacterial quinoline derivatives
EP2202231A4 (fr) Dérivé de 2,3-dihydroiminoisoindole
AP2322A (en) Antibacterial quinoline derivatives.
PL2099765T3 (pl) 5-, 6- lub 7-podstawione pochodne 3-aryloizochinolinoaminy jako środki przeciwnowotworowe
IL201444A0 (en) New 4, 8 - diphenyl - polyazanaphthalene derivatives
IL188111A0 (en) 2,5-bis-diamimne [1,4] benzoquinone-derivatives
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
IL193483A0 (en) 4-amino-1,5-substituted 1,5 - dihydro - imidazol -2- ones
PT2010509E (pt) Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona como agentes de dilatação do canal de potássio
GB0612774D0 (en) Molecular KNEX-structures, more specifically, molecular KNEX-DNA-structures
GB0623580D0 (en) Success, success, success, success
GB0623583D0 (en) Success, success, success
AU2006902453A0 (en) Trolley tracka tm.